Candel Therapeutics Fuels Growth with Promising Cancer Data & $130M Financing

NEW YORK, NY – November 13, 2025

Positive Data Drives Momentum in Prostate Cancer

Candel Therapeutics is experiencing a surge in momentum following the announcement of promising clinical trial data for its lead candidate, CAN-2409, in localized prostate cancer. The company reported statistically significant improvements in disease-free survival and prostate cancer-specific DFS, independent of radiation therapy regimen. These results, unveiled at recent medical conferences, demonstrate a potential advancement in a field that has seen limited innovation in decades.

“The data really speaks for itself,” said one oncology expert familiar with the trial. “To see a treatment demonstrate efficacy regardless of the radiation protocol is significant. It suggests this could become a valuable addition to the treatment paradigm.”

CAN-2409’s mechanism of action, utilizing oncolytic viral immunotherapy, aims to selectively infect and destroy cancer cells while also stimulating the body’s immune response. The company is on track to submit a Biologics License Application (BLA) to the FDA in Q4 2026, buoyed by the RMAT and Fast Track designations, which could accelerate the review process.

Expanding Horizons: Targeting Non-Small Cell Lung Cancer

Beyond prostate cancer, Candel is strategically expanding its pipeline to address the significant unmet need in non-small cell lung cancer (NSCLC). The company plans to initiate a pivotal Phase 3 trial for CAN-2409 in metastatic non-squamous NSCLC in Q2 2026. This move positions Candel within a highly competitive, multi-billion-dollar market, but also offers a potential opportunity to improve outcomes for patients who don’t respond adequately to current standard-of-care treatments.

The NSCLC market is dominated by immunotherapies and targeted therapies. Candel’s approach, which focuses on enhancing the immune system’s ability to recognize and attack cancer cells, could complement existing treatments and potentially overcome resistance mechanisms. Preliminary data from a Phase 2a trial suggests that CAN-2409 may enhance the effectiveness of immune checkpoint inhibitors, a key area of focus for the company. “We believe that by stimulating a stronger anti-tumor immune response, we can improve outcomes for patients who are not responding to existing therapies,” explained a company spokesperson.

$130M Financing Fuels Growth and Expansion

To support its clinical development programs and prepare for potential commercialization, Candel Therapeutics has secured a $130 million term loan facility with Trinity Capital Inc. The financing, which included an initial drawdown of $50 million, provides the company with a strong financial foundation and extends its cash runway into Q1 2027.

The loan proceeds will be used to refinance existing debt, fund working capital, support the Phase 3 NSCLC trial, and prepare for the BLA submission of CAN-2409 in prostate cancer. “This financing is a testament to the strength of our clinical data and the potential of our immunotherapy platform,” said one analyst covering the company. “It provides Candel with the resources it needs to execute on its strategic vision and bring its innovative therapies to patients.”

The terms of the financing are favorable, with an initial interest rate of 10.25% and a 36-month interest-only period. This structure allows Candel to conserve cash during the critical clinical development phase and prepare for potential revenue generation.

Promising Data in Recurrent Glioblastoma

While prostate cancer and NSCLC represent key strategic priorities, Candel is also making progress in the treatment of recurrent high-grade glioma, a particularly aggressive and challenging form of brain cancer. Recent data from a Phase 1b trial of CAN-3110 showed a median overall survival of 11.8 to 12 months, which is encouraging for a patient population with limited treatment options. Candel is planning a randomized Phase 2 trial to further evaluate the efficacy of CAN-3110 in this setting. “We are committed to developing innovative therapies for patients with all types of cancer, including those with particularly challenging diseases like glioblastoma,” said a company representative.

The combination of promising clinical data, strategic expansion into new indications, and a robust financial position positions Candel Therapeutics for a pivotal year in oncology innovation.